Abbott Laboratories (ABT) Stock Forecast for 2025, 2026, 2027. Sell or Buy Prediction







Top 5 Coins for the Maximum Passive Income from Staking by 2024

February 5, 2025 Top 5 Coins for the Maximum Passive Income from Staking by 2024

Staking is one of the ways that is now being used as a secure and profitable way to earn money without doing anything…
Trading Stocks With AI: A Modern Approach

January 21, 2025 Trading Stocks With AI: A Modern Approach

The stock market can feel overwhelming, especially with its constant ups and downs. Trading stocks with AI is revolutionizing how investors analyze trends,…
Bitcoin Is Great, but Here Are 3 Altcoins Worth Considering in 2025

January 21, 2025 Bitcoin Is Great, but Here Are 3 Altcoins Worth Considering in 2025

The launch of spot Bitcoin (CRYPTO: BTC) exchange-traded funds (ETFs) in January 2025 marked a turning point in the cryptocurrency market. These ETFs…
Advanced Charting Tools For Traders

January 1, 2025 Advanced Charting Tools For Traders

Ever tried deciphering market trends with the intensity of a detective peering over cryptic clues? Enter the realm of Advanced Charting, where complex…
Why Is Trading Important?

December 21, 2024 Why Is Trading Important?

Trade isn’t just figures on a spreadsheet; it’s the pulse of our global community. In 2018, the United States faced a staggering $621…

Abbott Laboratories (ABT) Stock Forecast for 2025, 2026, 2027. Sell or Buy?

Updated: February 6, 2025 (15:08)

Sector: Healthcare

The share price of Abbott Laboratories (ABT) now

Latest session on the 5th of February for
Abbott Laboratories is positive
Trading Volume: 8680447
Open: 129.43 /  High: 132.5 /  Low: 128.95
Current value: $132.06
What analysts predict: $133.08
52-week High/Low: $129.85 / $98.72
50-Day Moving Average: $116.6 — support level today
200-Day Moving Average: $111.22 — support level today

News Impact Analyzer

Full report
This Week
Na Impact: Na News: 1
Previous Week
Na Impact: Na News: Na
Two Weeks Ago
Bearish Impact: 1.56 News: 3 (1/0/2)
Three Weeks Ago
Bullish Impact: 5 News: 1 (1/0/0)

Analysts predictions

Full report
This Week
Neutral Opinions: Na
Previous Week
Bullish Opinions: 2 (2/0/0)
Two Weeks Ago
Neutral Opinions: Na
Three Weeks Ago
Bullish Opinions: 1 (1/0/0)

Analyzing the Most Important ABT news

FDA Warns Diabetes Device Users to Monitor Smartphone Alert Settings

Feb 05, 2025
Trend: Neutral
Influence: 4
The FDA advisory on alert settings for diabetes devices may raise mild concerns about user compliance, but it does not directly implicate ABT's product performance or regulatory issues. While it could trigger awareness among users, the financial impact on ABT is limited given the advisory's non-critical nature. Minimal short-term price influence is expected.

UBS Analyst Warns: One Step Away from a Bubble

Jan 23, 2025
Trend: Bearish
Influence: 7
The rising U.S. 10-year bond yield suggests higher borrowing costs, negatively affecting equities like ABT. With yields approaching 5%, investor sentiment may shift towards fixed-income securities, reducing demand for stocks. The anticipation of a market bubble adds further pressure, indicating a bearish trend for ABT with substantial influence on its stock price.

Abbott Dips as Q4 Revenue Falls Short

Jan 22, 2025
Trend: Bearish
Influence: 6
Abbott Laboratories' Q4 revenue miss despite MedTech division's success introduces a bearish sentiment, leading to a premarket dip. Analysts likely view the shortfall as a concerning sign for overall growth. The level of influence is moderate at 6, indicating that while impactful, the earnings miss is not catastrophic but could pressure the stock in the near term.

Historical and forecast chart of Abbott Laboratories stock

The chart below shows the historical price of Abbott Laboratories stock and a prediction chart for the next month. For convenience, prices are divided by color. Forecast prices include: Optimistic Forecast, Pessimistic Forecast, and Weighted Average Best Forecast. Detailed values for the Abbott Laboratories stock price can be found in the table below.

Long-term forecasts by years.

Abbott Laboratories Analysts predictions review

Abbott Laboratories (ABT) exhibits a bullish outlook driven by robust core revenue growth in its diagnostics and medical devices segments. Strategic investments in innovation, operational efficiency, and cost management enhance margins and sustain long-term growth potential. Additionally, the company benefits from its diversified product portfolio, mitigating risks and providing revenue stability across economic cycles. Key growth areas include chronic disease care and emerging markets, counterbalancing macroeconomic challenges such as exchange rate volatility and regulatory scrutiny. With easing supply chain pressures and a strong Q4 performance, ABT's valuation offers an attractive entry for long-term investors.

Abbott Laboratories: Solid Q4 Performance Signals Growth Opportunities

Trend: Bullish
Jan 26, 2025

Abbott Laboratories has delivered robust Q4 results, demonstrating strong core revenue growth, particularly in its medical devices and diagnostics divisions. The company's ability to capitalize on growing demand for innovative healthcare solutions positions it as a resilient performer in the sector. Such sustained growth in these segments underpins a positive outlook for long-term profitability.

Key Drivers Shaping ABT's Outlook

The author highlights Abbott's consistent focus on innovation and product pipeline expansion, which continue to attract investor confidence. By maintaining a strategy of developing market-leading products, particularly in high-growth categories, the company mitigates risks of market saturation and competitive pressure.

Additionally, Abbott's effective cost management and operational efficiency improvements significantly boost its profitability margins. These efforts underscore management's commitment to creating shareholder value, especially in a competitive macroeconomic environment.

The article focuses on ABT's ability to adapt to changing demographics and the rising demand for chronic disease management solutions. Such strategic alignment with global healthcare trends supports robust, sustainable growth for the company in the foreseeable future.


Analyst: ALLKA Research
( Followers: 1469
Articles: 51 )

Abbott Laboratories: Positioned for Growth Amid Renewed Value Opportunity

Trend: Bullish
Jan 23, 2025

Abbott Laboratories (ABT) has recently been highlighted as returning to an attractive valuation range, supported by fundamental strengths that signal potential upside for investors. A significant driving factor is the company's diversified healthcare portfolio, which includes market-leading products in diagnostics, medical devices, and nutritional segments. This broad base not only mitigates risks associated with reliance on any single sector but also provides stable revenue streams that can withstand market turbulence. The author underscores this diversification as a critical advantage for ABT's long-term growth trajectory.

Strong Financials and Strategic Positioning

Another key factor is Abbott's consistent financial performance, demonstrated through resilient revenue growth, robust free cash flow generation, and effective cost management. These metrics highlight the company's ability to navigate economic uncertainties, further supporting the stock’s valuation potential. The article also emphasizes Abbott’s strategic investments in innovation, particularly within its medical device and diagnostics segments, which address high-demand areas such as diabetes care and infectious disease testing. These initiatives position the company to capture significant growth in emerging markets and drive future revenue expansion.

Lastly, the upgrade in the stock's rating reflects a broader sentiment shift, likely influenced by improving macroeconomic conditions and easing pressures from supply chain disruptions seen earlier. While short-term headwinds remain in some of its operations, such as the post-pandemic normalization in diagnostics, the core business shows durable strength. The author concludes that ABT's current valuation presents a favorable entry point for long-term investors seeking a stable and growing player in the healthcare sector.


Analyst: Kody's Dividends
( Followers: 9699
Articles: 568 )

Assessing Abbott Laboratories’ Q4 2024 Growth Catalysts and Earnings Outlook

Trend: Bullish
Jan 08, 2025

Abbott Laboratories (ABT) is positioned to deliver strong results in Q4 2024, with significant contributions expected from its core diagnostics and medical device segments. Robust demand for these products, particularly in emerging markets, is expected to underpin revenue growth. Additionally, the company’s strategic focus on innovation has led to new launches in minimally invasive devices and advanced diagnostics, reinforcing its competitive edge.

Key Growth Drivers and Challenges

Operational efficiency continues to enhance Abbott's margins, supported by ongoing cost optimization initiatives and supply chain improvements. However, macroeconomic pressures, including foreign exchange volatility, could partially temper profit growth. While management has indicated confidence in navigating these challenges, currency headwinds remain a notable factor to monitor.

On the downside, the summary highlights potential risks related to regulatory scrutiny in certain international markets. These risks could delay product approvals and introduce compliance costs, slightly dampening the outlook. Nonetheless, the firm’s proven ability to adapt to regulatory environments instills confidence in a longer-term upward trajectory.


Analyst: Michael Dion
( Followers: 635
Articles: 111 )
Nov 25, 2024
Abbott Laboratories: Assessing Growth Potential Amid Valuation Concerns
Trend: Neutral

Abbott Laboratories' valuation appears elevated, causing potential hesitation among investors in the short term. The author notes that while the company has a strong market position, its current price-to-earnings ratio significantly exceeds historical and sector averages, suggesting limited upside from current levels.

Despite near-term uncertainties, Abbott's diversified product portfolio provides a robust foundation for sustained growth. The author highlights that its exposure to high-growth healthcare segments, such as medical devices and diagnostics, positions the company well to capture long-term demand in these markets.

Analyzing Revenue Trends and Capital Allocation

Recent revenue trends reflect solid performance, but softer growth in certain segments, such as nutrition, may temper overall expectations. However, the firm’s effective capital allocation strategy, including consistent dividend increases, underpins its appeal to income-focused investors.

Macroeconomic factors, including inflation and foreign exchange headwinds, could exert downside pressure on margins. Nevertheless, Abbott's operational resilience and innovation-driven approach may mitigate these risks and support its earnings trajectory over the medium term.

Analyst: Dividend Yield Theorist
( Followers: 8375
Articles: 251 )
Oct 23, 2024
Abbott Laboratories: Stable Growth Prospects Amid Valuation Concerns
Trend: Neutral

Abbott Laboratories demonstrates robust growth potential driven by its diversified healthcare portfolio, with a notable focus on its Diagnostics and Medical Devices segments. These divisions are poised to benefit from ongoing innovation and increased market adoption, reinforcing the company's ability to generate sustainable revenue growth over the long term.

Balancing Growth Potential and Valuation Metrics

Despite its strong fundamentals, the stock appears fully valued based on its current valuation metrics, as highlighted by the author. This may limit immediate upside potential, particularly in the absence of significant near-term catalysts or unexpected earnings surprises.

Macro-level challenges, such as inflationary pressures and potential interest rate increases, could act as near-term headwinds for operating margins. However, the company's strong balance sheet and operational resilience position it to navigate these challenges effectively over time, mitigating downside risks.

In summary, while the company's growth narrative remains compelling, valuation concerns and macroeconomic uncertainties may temper investor enthusiasm in the near term. Potential buyers may consider adopting a wait-and-watch approach until a more favorable entry point emerges.

Analyst: Weebler Finance
( Followers: 388
Articles: 58 )

Comprehensive Analysis of Abbott Laboratories (ABT) Stock Market Performance


Our multifaceted analysis of Abbott Laboratories's stock market is grounded in the company's key news stories, insights from reputable analysts, as well as mathematical and technical evaluations. Taking into account assessments from each of these aspects in real-time helps us address the most crucial questions for investors in the most objective way possible:

  • When should I take profit in Abbott Laboratories stock?
  • When should I record a loss on Abbott Laboratories stock?
  • What are analysts' forecasts for Abbott Laboratories stock?
  • What is the future of Abbott Laboratories stock?

We forecast Abbott Laboratories stock performance using neural networks based on historical data on Abbott Laboratories stocks.

Abbott Laboratories manufactures drugs, medical devices and diagnostic tools – tests for immunity and blood tests that are used in clinics and hospitals in N countries. The first HIV test was developed by Abbott.

Business publications and major stock indices recognize Abbott Laboratories’ contributions: Fortune magazine has ranked the company as one of the most respected in the world every year since 1984.

The company was founded in 1888. The University of Michigan graduate Wallace Abbott worked as a medical practitioner and opened his own pharmacy. He introduced a new way of using alkaloids of medicinal plants: he formed granules from them with micro doses. Treatment with these granules helped patients because the doses of the drug were accurate and the effect was predictable and consistent.

Official site of the company

Abbott Laboratories News influencing stock rates

As of now, Panda has combed through 5 news items directly related to ABT from the last 30 days. Out of these, 2 clearly showcase a bullish trend, while 2 display bearish tendencies, and 1 events are neutral.

The strength of the bullish trend outpaces the bearish sentiments by 1.14 times, indicating that the news backdrop is positively influencing the company’s stock price in the current outlook.

The news analyzed fell within the period from Jan 13, 2025, to Feb 05, 2025.

βeta
Jan 22, 2025

Abbott Shatters Records with Peak Medical Device Sales

Trend: Bullish
Influence: 8
Abbott's Q4 record-breaking sales in Medical Devices signifies robust growth and operational strength in a core business segment. Such financial performance often leads to positive investor sentiment, suggesting a potential rise in stock prices. Given its significant contribution to overall revenue, this achievement indicates strong future prospects, marking a highly influential development for the stock's trajectory.
Jan 13, 2025

Insulet Expands Omnipod 5 Across Europe: Boost for Abbott's CGM Partnership

Trend: Bullish
Influence: 7
The launch of the Omnipod 5 system in five European countries is a positive development for Abbott Laboratories as it strengthens the collaboration through use of its FreeStyle Libre 2 Plus glucose monitors. This expansion can drive demand and increased sales in Europe, positively impacting Abbott's revenue and stock price in the near term.
Jan 06, 2025

FDA Draft Guidance: AI's Role in Drug and Device Innovation

Trend: Bullish
Influence: 7
The FDA's draft guidance on AI in drug development and medical devices suggests an increased regulatory support for integrating AI in healthcare, which bodes well for innovation at companies like Abbott (ABT). As a leader in medical devices, ABT may benefit from streamlined approval processes and enhanced product development, positively influencing its stock in the near future.
Dec 23, 2024

Abbott and DexCom Strike a Decade-Long Patent Peace

Trend: Bullish
Influence: 6
The settlement between Abbott and DexCom, resolving patent disputes and ensuring no litigation for 10 years, suggests stability and potential collaborative innovation, which is seen positively by investors. However, with no financial transactions involved, the direct impact on Abbott's stock price may be moderate. Therefore, the trend is 'Bullish' but with a medium influence level.
Dec 13, 2024

Abbott Laboratories Boosts Dividend by 7.3%, Signaling Growth

Trend: Bullish
Influence: 8
The increase in ABT's quarterly dividend indicates strong financial health and a commitment to returning value to shareholders. A 7.3% hike, combined with a 60% rise since 2020, can enhance investor confidence, potentially driving stock demand. Such consistent growth positively influences market perception, making the stock trend bullish with a significant impact on prices.
Nov 26, 2024

Abbott's Legal Setback: $500M Baby Formula Verdict Stands

Trend: Bearish
Influence: 7
The judge's denial of Abbott's retrial request and the maintenance of a $500 million penalty represents a significant financial and reputational setback, influencing investor perceptions negatively. This situation could reignite concerns about potential liabilities and litigation costs, causing a downward pressure on the stock. The importance and size of the verdict justify a relatively high influence rating.
Nov 23, 2024

Mpox Emergency: WHO's Global Action and Canada's Clade I Case Highlighted

Trend: Neutral
Influence: 3
The WHO's extended mpox emergency and Canada's first Clade I case are important public health updates but have limited immediate impact on ABT's stock. ABT, a healthcare company, may see longer-term interest if involved in testing or treatment solutions. However, immediate financial ramifications are minimal, leading to a neutral trend with low influence on stock price.
Nov 21, 2024

Rising Optimism Signals Growth in Global Healthcare Investments

Trend: Bullish
Influence: 7
The rising optimism in the healthcare sector and expected increase in M&A activities indicates a favorable environment for healthcare companies like Abbott (ABT). This positive sentiment could drive investor interest and stock performance. The strong focus on mid- and small-cap pharma and biotech sectors adds a supportive backdrop, making the trend bullish with significant influence.
Nov 20, 2024

Insulet's Omnipod 5 Enhances Diabetes Management with Abbott Sensor Integration

Trend: Bullish
Influence: 7
Abbott's integration with Insulet's Omnipod 5 strengthens its position in the diabetes management market, boosting its FreeStyle Libre 2 Plus utility. This development could lead to increased usage and sales for Abbott, positively impacting its stock. The FDA approval further substantiates the product's efficacy, supporting a bullish outlook for Abbott in the near term.
Nov 17, 2024

First U.S. Mpox Case from Africa Sparks Health Alert

Trend: Neutral
Influence: 3
The mpox case in the U.S. is noteworthy but unlikely to have a significant impact on Abbott Laboratories (ABT), as their exposure to the mpox market is limited. The event's isolated nature suggests minimal influence on financials or investor sentiment, maintaining a neutral trend for ABT's stock price in the near term.

Trending Themes in the Healthcare Sector

Abbott Laboratories daily forecast for a month

Date Target Pes. Opt. Vol., %
Feb 08 131.37 129.96 133.37 2.63
Feb 09 131.11 129.93 132.97 2.34
Feb 10 128.49 126.46 129.29 2.24
Feb 11 128.80 127.97 130.01 1.59
Feb 12 130.50 129.90 131.36 1.13
Feb 13 129.74 127.87 131.04 2.48
Feb 14 130.18 128.31 131.48 2.48
Feb 15 131.41 129.96 132.19 1.72
Feb 16 129.33 127.86 130.16 1.80
Feb 17 128.99 127.19 130.46 2.58
Feb 18 128.56 127.01 129.30 1.80
Feb 19 130.46 129.65 131.42 1.37
Feb 20 131.34 130.64 132.21 1.21
Feb 21 130.58 129.88 131.50 1.25
Feb 22 129.41 128.81 130.42 1.25
Feb 23 128.79 127.58 129.51 1.51
Feb 24 128.74 127.47 130.33 2.24
Feb 25 127.65 126.66 129.03 1.88
Feb 26 126.17 125.34 126.96 1.29
Feb 27 124.84 123.24 126.01 2.25
Feb 28 124.16 122.30 124.66 1.93
Mar 01 123.81 122.90 124.51 1.31
Mar 02 126.29 125.56 126.85 1.03
Mar 03 127.68 126.63 128.93 1.81
Mar 04 129.39 128.43 131.33 2.26
Mar 05 131.12 129.31 131.88 1.99
Mar 06 131.41 130.49 132.86 1.81
Mar 07 132.73 131.43 134.53 2.36
Mar 08 130.55 129.35 131.20 1.43
Mar 09 128.07 126.48 128.58 1.66

Abbott Laboratories Daily Price Targets


Abbott Laboratories Stock Forecast 02-08-2025.

Forecast target price for 02-08-2025: $131.37.
Negative dynamics for Abbott Laboratories shares will prevail with possible volatility of 2.561%.
Pessimistic target level: 129.96
Optimistic target level: 133.37

Abbott Laboratories Stock Forecast 02-09-2025.

Forecast target price for 02-09-2025: $131.11.
Negative dynamics for Abbott Laboratories shares will prevail with possible volatility of 2.288%.
Pessimistic target level: 129.93
Optimistic target level: 132.97

Abbott Laboratories Stock Forecast 02-10-2025.

Forecast target price for 02-10-2025: $128.49.
Negative dynamics for Abbott Laboratories shares will prevail with possible volatility of 2.187%.
Pessimistic target level: 126.46
Optimistic target level: 129.29

Abbott Laboratories Stock Forecast 02-11-2025.

Forecast target price for 02-11-2025: $128.80.
Positive dynamics for Abbott Laboratories shares will prevail with possible volatility of 1.565%.
Pessimistic target level: 127.97
Optimistic target level: 130.01

Abbott Laboratories Stock Forecast 02-12-2025.

Forecast target price for 02-12-2025: $130.50.
Positive dynamics for Abbott Laboratories shares will prevail with possible volatility of 1.113%.
Pessimistic target level: 129.90
Optimistic target level: 131.36

Abbott Laboratories Stock Forecast 02-13-2025.

Forecast target price for 02-13-2025: $129.74.
Negative dynamics for Abbott Laboratories shares will prevail with possible volatility of 2.416%.
Pessimistic target level: 127.87
Optimistic target level: 131.04

ABT (ABT) Monthly Stock Prediction for 2025

Month Target Pes. Opt. Vol., %
Mar. 127.32 120.49 133.22 9.56
Apr. 124.87 119.68 128.27 6.70
May. 125.27 117.66 127.48 7.70
Jun. 120.56 113.04 126.35 10.53
Jul. 123.07 118.44 129.96 8.86
Aug. 132.82 126.87 136.96 7.37
Sep. 142.70 134.14 148.29 9.55
Oct. 145.21 142.54 151.71 6.05
Nov. 143.81 137.49 151.29 9.13
Dec. 139.67 133.08 142.24 6.44

Abbott Laboratories forecast for this year


Abbott Laboratories Stock Prediction for Mar 2025

An downtrend is forecast for this month with an optimal target price of $127.316. Pessimistic: $120.49. Optimistic: $133.22


Abbott Laboratories Stock Prediction for Apr 2025

An downtrend is forecast for this month with an optimal target price of $124.871. Pessimistic: $119.68. Optimistic: $128.27


Abbott Laboratories Stock Prediction for May 2025

An uptrend is forecast for this month with an optimal target price of $125.271. Pessimistic: $117.66. Optimistic: $127.48


Abbott Laboratories Stock Prediction for Jun 2025

An downtrend is forecast for this month with an optimal target price of $120.561. Pessimistic: $113.04. Optimistic: $126.35


Abbott Laboratories Stock Prediction for Jul 2025

An uptrend is forecast for this month with an optimal target price of $123.069. Pessimistic: $118.44. Optimistic: $129.96


Abbott Laboratories Stock Prediction for Aug 2025

An uptrend is forecast for this month with an optimal target price of $132.816. Pessimistic: $126.87. Optimistic: $136.96


Abbott Laboratories Stock Prediction for Sep 2025

An uptrend is forecast for this month with an optimal target price of $142.697. Pessimistic: $134.14. Optimistic: $148.29


Abbott Laboratories Stock Prediction for Oct 2025

An uptrend is forecast for this month with an optimal target price of $145.209. Pessimistic: $142.54. Optimistic: $151.71


Abbott Laboratories Stock Prediction for Nov 2025

An downtrend is forecast for this month with an optimal target price of $143.814. Pessimistic: $137.49. Optimistic: $151.29


Abbott Laboratories Stock Prediction for Dec 2025

An downtrend is forecast for this month with an optimal target price of $139.673. Pessimistic: $133.08. Optimistic: $142.24



Abbott Laboratories (ABT) Monthly Stock Prediction for 2026

Month Target Pes. Opt. Vol., %
Jan 137.77 135.46 141.08 3.98
Feb 132.04 127.50 137.64 7.37
Mar 142.08 134.12 151.06 11.21
Apr 145.15 140.27 147.47 4.88
May 150.14 144.25 152.66 5.51
Jun 153.98 147.58 160.14 7.85
Jul 149.30 146.55 157.07 6.69
Aug 158.62 152.15 162.68 6.47
Sep 169.40 165.34 180.25 8.27
Oct 164.39 161.50 171.36 5.76
Nov 162.94 154.99 172.20 9.99
Dec 158.38 154.58 165.35 6.51

Abbott Laboratories (ABT) Monthly Stock Prediction for 2027

Month Target Pes. Opt. Vol., %
Jan 157.75 153.33 161.66 5.15
Feb 165.07 155.96 174.31 10.53
Mar 160.18 154.41 165.05 6.44
Apr 167.87 163.44 177.14 7.73
May 170.56 161.55 176.70 8.57
Jun 168.24 159.89 178.46 10.41
Jul 160.83 154.91 169.97 8.86
Aug 155.94 152.95 159.19 3.92
Sep 157.69 152.39 163.12 6.57
Oct 169.80 160.43 178.50 10.12
Nov 177.00 173.32 188.05 7.83
Dec 184.36 176.69 193.51 8.69

Abbott Laboratories information and performance

Abbott Laboratories Address

100 ABBOTT PARK ROAD, ABBOTT PARK, IL, US

Market Capitalization: 221 889 479 000 $

Market capitalization of the Abbott Laboratories is the total market value of all issued shares of a company. It is calculated by the formula multiplying the number of ABT shares in the company outstanding by the market price of one share.

EBITDA: 10 825 000 000 $

EBITDA of Abbott Laboratories is earnings before interest, income tax and depreciation of assets.

PE Ratio: 16.74

P/E ratio (price to earnings) - shows the ratio between the price of a share and the company's profit

PEG Ratio: 2.3

Price/earnings to growth

DPS: N/A

Dividend Per Share is a financial indicator equal to the ratio of the company's net profit available for distribution to the annual average of ordinary shares.

DY: 0.0202

Dividend yield is a ratio that shows how much a company pays in dividends each year at the stock price.

EPS: 7.64

EPS shows how much of the net profit is accounted for by the common share.

Quarterly Earnings Growth YOY: 0.146
Quarterly Revenue Growth YOY: 0.049
Trailing PE: 16.74

Trailing P/E depends on what has already been done. It uses the current share price and divides it by the total earnings per share for the last 12 months.

Forward PE: 24.81

Forward P/E uses projections of future earnings instead of final numbers.

EV To Revenue: 5.46

Enterprise Value (EV) /Revenue

EV To EBITDA: 25.16

The EV / EBITDA ratio shows the ratio of the cost (EV) to its profit before tax, interest and amortization (EBITDA).

Shares Outstanding: 1734460000

Number of issued ordinary shares

Shares Float: N/A

Number of freely tradable shares

Shares Short Prior Month: N/A

Shares Short Prior Month - the number of shares in short positions in the last month.

Short Ratio: N/A
Percent Insiders: N/A
Percent Institutions: N/A

Abbott Laboratories (ABT) stock dividend

Abbott Laboratories last paid dividends on 01/15/2025. The next scheduled payment will be on 02/14/2025. The amount of dividends is $0 per share. If the date of the next dividend payment has not been updated, it means that the issuer has not yet announced the exact payment. As soon as information becomes available, we will immediately update the data. Bookmark our portal to stay updated.

Last Split Factor:

Last Split Date: 01/01/1970

Splitting of shares is an increase in the number of securities of the issuing company circulating on the market due to a decrease in their value at constant capitalization.

For example, a 5: 1 ratio means that the value of one share will decrease 5 times, the total amount will increase 5 times. It is important to understand that this procedure does not change the capitalization of the company, as well as the total value of assets held in private hands.

FAQ (Frequently Asked Questions about Abbott Laboratories Stock)

Should I Buy Abbott Laboratories Shares in 2025 year?

The maximum forecasted share price for next year is $169.40, which is $37.34 higher than the current stock price. By investing in Abbott Laboratories shares today for a one-year period, you could achieve a profit of 28.28%. With an investment horizon of up to two years, the target share price is $184.36. resulting in a profit of 39.61% ($52.30 per share).

Does Abbott Laboratories pay dividends?

No, it does not

Which economic sector do Abbott Laboratories's shares belong to?

Abbott Laboratories's shares belong to the "Healthcare" sector of economic.

Which other securities belong to the same sector as Abbott Laboratories's shares?

You can view all the stocks that are part of the same sector as Abbott Laboratories's shares in the Healthcare section.


Related stocks from Healthcare sector


Disclaimer:

All forecast data on the site are provided for informational purposes of using neural forecasting tools in the financial market and are not a call to action and, moreover, are not trading signals. When using the forecast data, the investor assumes all financial risks. The pandaforecast.com portal is not responsible for the loss of your money in the stock market as a result of using the information contained on the site.